News
Can Antihypertensives Reduce the Risk of Dementia? The Answer Suggests the Angiotensin Hypothesis and a Post-Hoc Analysis of an Observational Study
The use of antihypertensives that do not reduce angiotensin II levels, such as angiotensin receptor blockers (ARBs, i.e., sartans) and calcium channel blockers (CCBs), has been associated with a lower risk of dementia in studies. In the research cited below, the authors aimed to determine whether this effect persists longer than the follow-up period in previous studies.
What Results Does Bimekizumab Achieve in Patients with PsA After 3 Years of Treatment?
Fresh findings from the BE ACTIVE study were published this year in the journal Rheumatology, which evaluated the effects of long-term treatment of individuals with psoriatic arthritis (PsA) with…
Can Empagliflozin Also Act Against Gout?
Gliflozins, or sodium-glucose cotransporter 2 inhibitors (SGLT2i), are not only effective antidiabetic agents but also exhibit cardio - and renoprotective effects. It now appears that in type 2…
How does the level of uric acid affect the incidence of cardiorenal events in patients with T2DM and CVD?
One of the post hoc analyses of the well-known EMPA-REG OUTCOME study provided data on the relationship between uric acid levels and the incidence of cardiorenal events in type 2 diabetics with…
Treatment of Schizophrenia in a Patient at Risk of Developing Metabolic Syndrome – Interactive Case Study
A 34-year-old man has been under psychiatric care for 3 years due to a psychotic disorder. Three years ago, he had his first short hospitalization due to marked paranoid symptoms: feelings of being watched,...
Currently on the Issue of Interchangeability of Preparations with Levothyroxine in Practice
Levothyroxine (LT4) in oral form is the standard therapy for patients with hypothyroidism. Given the legislative possibility of generic substitution and the number of original and generic preparations...
INFOGRAPHIC: Determining the Target Intraocular Pressure in Glaucoma Therapy
The goal of glaucoma treatment is to preserve the visual field and the quality of life of patients. Currently, the only approach to preserving the visual field of patients is to reduce intraocular…
Effectiveness of Bisoprolol in Patients with Cardiac Arrhythmias – A Systematic Review of Studies
Last year, a Franco-Romanian team published a study that conducted a systematic review of existing evidence on bisoprolol in the context of arrhythmia treatment. The authors noted that bisoprolol,…
Which biomarkers can be used for risk stratification in ATTR cardiac amyloidosis?
Effective treatment for patients with transthyretin cardiac amyloidosis requires timely diagnosis and precise risk stratification to identify patients at higher risk of cardiovascular events, heart…
Results of a 10-year follow-up on the safety and efficacy of etanercept treatment in patients with juvenile idiopathic arthritis
Juvenile idiopathic arthritis (JIA) is defined as persistent arthritis of unknown etiology lasting > 6 weeks with the first onset before the age of 16. In the treatment of JIA, non-steroidal…
Tofacitinib Through the Eyes of Patients: Rapid Response After Treatment Initiation
How does tofacitinib fare in the treatment of ulcerative colitis in real clinical practice from the patients' perspective? This was addressed in a recent study published in the journal Inflammatory…
Mental Health as an Overlooked Topic in Patients with Psoriasis
Psoriasis is an inflammatory, non-infectious disease primarily affecting the skin, and sometimes the nails, although in some patients, it manifests as psoriatic arthritis. To minimize the negative…
Current Expert Consensus on Prophylaxis of Individuals with Mild and Moderate Hemophilia A: These Patients Also Deserve Better Care
What is the importance of prophylaxis in 'non-severe' hemophilia A? Italian doctors have attempted to answer this question in their recent expert consensus.
Non-factor vs. Factor Prophylaxis of Hemophilia A: A Comparison of Cost and Treatment Effectiveness Based on Real-World Data from the USA
In the prophylactic treatment of patients with hemophilia A, particularly its severe form, concentrates of clotting factor VIII (FVIII) with extended half-life (EHL) are increasingly administered, or…
When to Suspect Dravet Syndrome?
In 2022, an international consensus panel of experts on the diagnosis and treatment of Dravet syndrome was published. This was created due to the recently approved specific treatments for this…